# When the Primary Endpoint Fails and a Secondary Doesn't

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/semaglutide-depression-cognition-trial

> A randomized trial in 72 people with major depressive disorder found no effect on executive function, its primary outcome. A secondary cognition measure cleared p=0.03, and that is the one that will be reported.

## Key points

- Primary endpoint (executive function): p=0.60, interval spanning zero.
- A secondary cognition measure hit p=0.03 in a 72-person trial. That is a suggestion, not a finding.
- No effect on depressive symptom severity, so semaglutide did not treat mood here.
- No increase in suicidal ideation, in the population where that concern is sharpest.

A randomized trial gave oral semaglutide or placebo to 72 people with major depressive disorder, to see whether it improved the cognitive difficulties that often come with depression. It did not improve the outcome it was built to test. A secondary measure did come back significant, and that is the one you will hear about.[1]

## What the trial found

*Outcomes from the trial, in the order they were pre-specified.*

| Outcome | Result | Status |
| --- | --- | --- |
| **Executive function** (primary) | 0.32 (95% CI −0.92 to 1.58), p=0.60 | No effect |
| Global cognition (secondary) | 2.39 (95% CI 0.19 to 4.60), p=0.03 | Significant |
| Body weight (secondary) | −6.03 kg (95% CI −8.76 to −3.29) | Significant |
| Depressive symptom severity | No effect | — |
| Frequency of suicidal ideation | No effect | — |

The primary outcome was a composite of the digit symbol substitution test, the Stroop test and an n-back task, all standard measures of executive function. Its confidence interval runs from clearly negative to clearly positive, which is what a null result in a small trial looks like.[1]

## Why the secondary result should not be the headline

A pre-specified primary endpoint exists precisely so that a trial cannot go looking for a win after the fact. A null trial becomes a positive headline when only the secondary result is reported. When the primary fails and a secondary succeeds, three things are true at once.

1. **The trial answered its question, and the answer was no.** That is the finding.
2. **Seventy-two people is small.** With several secondary outcomes measured, one clearing p=0.05 is unremarkable arithmetic, as [a semaglutide cognition trial in people with HIV](https://glpwatchdog.org/research/three-domains-improved-then-one) also showed.
3. **A p of 0.03 with a lower bound of 0.19** is a result that barely clears the line, in a measure that was not the target.

> The headline is the failed primary. The secondary is a suggestion for the next trial.

That is not a criticism of the researchers, who reported all of it plainly and used appropriately cautious language, describing the secondary results as suggesting effects on specific domains. It is a warning about what happens to a result like this on its way to a reader.

## The two findings that are actually useful

**It did not improve depression.** Depressive symptom severity was unchanged. Anyone hoping these drugs treat mood directly, rather than the metabolic burden that often accompanies it, has an answer here.

**It did not increase suicidal ideation.** The frequency of suicidal ideation was unaffected, and there were no serious adverse events.[1] That is a small data point in a much larger question we cover in [what happened with the suicidality signal](https://glpwatchdog.org/research/glp1-suicidal-ideation-what-happened). It also comes from people with major depressive disorder, the population where the concern is sharpest.

> Gastrointestinal side effects were common and no serious adverse events occurred. The authors’ own summary is that semaglutide was safe for patients with major depressive disorder, which is a useful conclusion from a trial that missed its primary endpoint.

## Frequently asked questions

### Does semaglutide improve cognition in depression?

Not on the measure the trial was designed around. Executive function showed no effect: 0.32, with a confidence interval from −0.92 to 1.58 (p=0.60). A secondary global cognition measure did reach significance at p=0.03, but that arrived after the primary endpoint failed, in a trial of 72 people.

### Why does it matter which endpoint was primary?

Because the primary is declared before the data exist, so it cannot be chosen to fit the result. When a primary fails and a secondary succeeds in a small trial with several outcomes, the secondary is a suggestion for the next study rather than a finding.

### Did it help depression itself?

No. Depressive symptom severity was unchanged. If these drugs help people with depression, this trial gives no evidence that it happens through a direct effect on mood.

### Did it increase suicidal thoughts?

No. The frequency of suicidal ideation was unaffected and there were no serious adverse events. That is a small but relevant data point, because it comes from people with major depressive disorder, the population where the concern is sharpest.

### Did participants lose weight?

Yes, about 6 kg more than placebo, which was one of the secondary outcomes and is consistent with the drug's known effect.

## References

1. Badulescu S, Gill H, Shah H, et al. Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial. Med. 2026. PMID: 41218611. https://pubmed.ncbi.nlm.nih.gov/41218611/

---

Cite as: GLP Watchdog, Nora Bissett, "When the Primary Endpoint Fails and a Secondary Doesn't", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/semaglutide-depression-cognition-trial

Canonical HTML page: https://glpwatchdog.org/research/semaglutide-depression-cognition-trial

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
